|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ATP5F1E |
Gene summary for ATP5F1E |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ATP5F1E | Gene ID | 514 |
| Gene name | ATP synthase F1 subunit epsilon | |
| Gene Alias | ATP5E | |
| Cytomap | 20q13.32 | |
| Gene Type | protein-coding | GO ID | GO:0006091 | UniProtAcc | P56381 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 514 | ATP5F1E | GSM4909281 | Human | Breast | IDC | 2.59e-20 | 3.75e-01 | 0.21 |
| 514 | ATP5F1E | GSM4909282 | Human | Breast | IDC | 6.02e-23 | 5.15e-01 | -0.0288 |
| 514 | ATP5F1E | GSM4909285 | Human | Breast | IDC | 5.53e-35 | 2.69e-01 | 0.21 |
| 514 | ATP5F1E | GSM4909286 | Human | Breast | IDC | 5.99e-32 | 5.51e-01 | 0.1081 |
| 514 | ATP5F1E | GSM4909287 | Human | Breast | IDC | 2.39e-31 | 5.99e-01 | 0.2057 |
| 514 | ATP5F1E | GSM4909289 | Human | Breast | IDC | 1.97e-07 | 5.66e-01 | 0.1064 |
| 514 | ATP5F1E | GSM4909290 | Human | Breast | IDC | 1.59e-31 | 6.51e-01 | 0.2096 |
| 514 | ATP5F1E | GSM4909291 | Human | Breast | IDC | 6.17e-30 | 6.76e-01 | 0.1753 |
| 514 | ATP5F1E | GSM4909293 | Human | Breast | IDC | 7.20e-55 | 7.54e-01 | 0.1581 |
| 514 | ATP5F1E | GSM4909294 | Human | Breast | IDC | 9.29e-35 | 7.31e-01 | 0.2022 |
| 514 | ATP5F1E | GSM4909295 | Human | Breast | IDC | 3.16e-09 | 4.75e-01 | 0.0898 |
| 514 | ATP5F1E | GSM4909296 | Human | Breast | IDC | 1.30e-27 | 6.74e-01 | 0.1524 |
| 514 | ATP5F1E | GSM4909297 | Human | Breast | IDC | 5.82e-32 | 6.23e-01 | 0.1517 |
| 514 | ATP5F1E | GSM4909298 | Human | Breast | IDC | 5.11e-49 | 7.58e-01 | 0.1551 |
| 514 | ATP5F1E | GSM4909299 | Human | Breast | IDC | 5.87e-25 | 5.76e-01 | 0.035 |
| 514 | ATP5F1E | GSM4909300 | Human | Breast | IDC | 1.43e-13 | 5.15e-01 | 0.0334 |
| 514 | ATP5F1E | GSM4909301 | Human | Breast | IDC | 4.92e-108 | 9.88e-01 | 0.1577 |
| 514 | ATP5F1E | GSM4909302 | Human | Breast | IDC | 3.46e-20 | 5.01e-01 | 0.1545 |
| 514 | ATP5F1E | GSM4909303 | Human | Breast | IDC | 1.44e-14 | 6.74e-01 | 0.0438 |
| 514 | ATP5F1E | GSM4909304 | Human | Breast | IDC | 9.25e-81 | 8.84e-01 | 0.1636 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000914418 | Prostate | Tumor | purine nucleoside triphosphate metabolic process | 38/3246 | 88/18723 | 1.28e-08 | 4.66e-07 | 38 |
| GO:000925918 | Prostate | Tumor | ribonucleotide metabolic process | 110/3246 | 385/18723 | 2.45e-08 | 8.29e-07 | 110 |
| GO:000616319 | Prostate | Tumor | purine nucleotide metabolic process | 111/3246 | 396/18723 | 6.46e-08 | 1.88e-06 | 111 |
| GO:001969318 | Prostate | Tumor | ribose phosphate metabolic process | 111/3246 | 396/18723 | 6.46e-08 | 1.88e-06 | 111 |
| GO:000920517 | Prostate | Tumor | purine ribonucleoside triphosphate metabolic process | 35/3246 | 82/18723 | 6.76e-08 | 1.95e-06 | 35 |
| GO:190260016 | Prostate | Tumor | proton transmembrane transport | 55/3246 | 157/18723 | 6.83e-08 | 1.96e-06 | 55 |
| GO:001598516 | Prostate | Tumor | energy coupled proton transport, down electrochemical gradient | 17/3246 | 26/18723 | 7.05e-08 | 1.99e-06 | 17 |
| GO:001598616 | Prostate | Tumor | ATP synthesis coupled proton transport | 17/3246 | 26/18723 | 7.05e-08 | 1.99e-06 | 17 |
| GO:007252119 | Prostate | Tumor | purine-containing compound metabolic process | 115/3246 | 416/18723 | 8.47e-08 | 2.31e-06 | 115 |
| GO:000914517 | Prostate | Tumor | purine nucleoside triphosphate biosynthetic process | 31/3246 | 69/18723 | 9.10e-08 | 2.45e-06 | 31 |
| GO:000920617 | Prostate | Tumor | purine ribonucleoside triphosphate biosynthetic process | 30/3246 | 68/18723 | 2.40e-07 | 5.65e-06 | 30 |
| GO:000919916 | Prostate | Tumor | ribonucleoside triphosphate metabolic process | 35/3246 | 89/18723 | 7.39e-07 | 1.47e-05 | 35 |
| GO:004277616 | Prostate | Tumor | mitochondrial ATP synthesis coupled proton transport | 13/3246 | 19/18723 | 1.19e-06 | 2.24e-05 | 13 |
| GO:000914217 | Prostate | Tumor | nucleoside triphosphate biosynthetic process | 33/3246 | 85/18723 | 2.13e-06 | 3.64e-05 | 33 |
| GO:000920116 | Prostate | Tumor | ribonucleoside triphosphate biosynthetic process | 30/3246 | 74/18723 | 2.13e-06 | 3.64e-05 | 30 |
| GO:000914118 | Prostate | Tumor | nucleoside triphosphate metabolic process | 40/3246 | 112/18723 | 2.30e-06 | 3.91e-05 | 40 |
| GO:000675416 | Prostate | Tumor | ATP biosynthetic process | 25/3246 | 57/18723 | 2.71e-06 | 4.52e-05 | 25 |
| GO:000915218 | Prostate | Tumor | purine ribonucleotide biosynthetic process | 53/3246 | 169/18723 | 5.62e-06 | 8.63e-05 | 53 |
| GO:199054217 | Prostate | Tumor | mitochondrial transmembrane transport | 36/3246 | 102/18723 | 9.84e-06 | 1.43e-04 | 36 |
| GO:000926016 | Prostate | Tumor | ribonucleotide biosynthetic process | 54/3246 | 182/18723 | 2.71e-05 | 3.29e-04 | 54 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
| hsa0502016 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
| hsa0501616 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
| hsa0019016 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
| hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0501416 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
| hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
| hsa0520818 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
| hsa0471418 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
| hsa0541518 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
| hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
| hsa0502017 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
| hsa0501617 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
| hsa0019017 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
| hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0501417 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
| hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
| hsa0520819 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
| hsa0471419 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
| hsa0541519 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 514 | ATP5F1E | TRANSPORTER | glucocorticoids | 26307125 | ||
| 514 | ATP5F1E | TRANSPORTER | etanercept | ETANERCEPT | 26307125 | |
| 514 | ATP5F1E | TRANSPORTER | adalimumab | ADALIMUMAB | 26307125 | |
| 514 | ATP5F1E | TRANSPORTER | certolizumab pegol | 26307125 | ||
| 514 | ATP5F1E | TRANSPORTER | methotrexate | METHOTREXATE | 26307125 | |
| 514 | ATP5F1E | TRANSPORTER | infliximab | INFLIXIMAB | 26307125 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |